Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KRYSTAL BIOTECH, INC.

(KRYS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Krystal Biotech : to Participate in Upcoming Investor Conferences

06/03/2021 | 08:01am EDT

PITTSBURGH, June 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual investor conferences.

Details for the events are as follows:

Goldman Sachs 42nd Annual Global Healthcare Conference
Date:Thursday, June 10, 2021
Time:11:20 AM ET
Webcast link:https://kvgo.com/gs-global-healthcare/krystal-biotech-june-2021


LifeSci Partners Genetic Medicines Summit 2021
Date:Tuesday, June 22, 2021
Location:Virtual

About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information please visit http://www.krystalbio.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about the development of Krystal’s product candidates, such as plans for the design, conduct and timelines of ongoing pre-clinical and clinical trials of beremagene geperpavec (“B-VEC”), KB105, KB104, KB301, KB407, and KB408; the clinical utility of B-VEC, KB105, KB104, KB301, KB407 and KB408, and Krystal’s plans for filing of regulatory approvals and efforts to bring B-VEC, KB105, KB104, KB301, KB407 and KB408 to market; the market opportunity for and the potential market acceptance of B-VEC, KB105, KB104, KB301, KB407 and KB408; plans to pursue research and development of other product candidates; the sufficiency of Krystal’s existing cash resources; the unanticipated impact of COVID-19 on Krystal’s business operations, pre-clinical activities and clinical trials; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including B-VEC, KB105, KB104, KB301, KB407 and KB408, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption “Risk Factors” in Krystal’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal’s views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal’s views as of any date subsequent to the date of this release.

CONTACTS:

Investors:
Whitney Ijem
wijem@krystalbio.com

Media:
Mary Coyle
TellMed Strategies
mary.coyle@tmstrat.com

Source: Krystal Biotech, Inc.


Primary Logo

Source: Krystal Biotech, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about KRYSTAL BIOTECH, INC.
07/21NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
07/20KRYSTAL BIOTECH : Goldman Sachs Lifts Krystal Biotech to Buy From Neutral, Price..
MT
07/07KRYSTAL BIOTECH, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
07/01KRYSTAL BIOTECH : Provides Update on the Clinical Trial Evaluating Topical KB105..
PU
07/01KRYSTAL BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhib..
AQ
07/01KRYSTAL BIOTECH : Reports Updated Data for Prospective Treatment of TGM-1 Associ..
MT
07/01Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB10..
GL
07/01Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB10..
CI
06/25KRYSTAL BIOTECH, INC.(NASDAQGM : KRYS) added to Russell Small Cap Comp Value Ind..
CI
06/25KRYSTAL BIOTECH, INC.(NASDAQGM : KRYS) added to Russell 3000E Value Index
CI
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -86,9 M - -
Net cash 2021 346 M - -
P/E ratio 2021 -16,1x
Yield 2021 -
Capitalization 1 329 M 1 329 M -
EV / Sales 2021 -
EV / Sales 2022 3,14x
Nbr of Employees 75
Free-Float 75,4%
Chart KRYSTAL BIOTECH, INC.
Duration : Period :
Krystal Biotech, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KRYSTAL BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 59,85 $
Average target price 102,13 $
Spread / Average Target 70,6%
EPS Revisions
Managers and Directors
Krish S. Krishnan Chairman, President & Chief Executive Officer
George Chen Manager-Information Technology & CSV
Trevor Parry Director-IP & Scientific Affairs
Brittani Agostini Manager-Clinical Operations
Court Freedman Senior Scientist
Sector and Competitors
1st jan.Capi. (M$)
KRYSTAL BIOTECH, INC.-2.78%1 295
GILEAD SCIENCES, INC.20.25%87 868
BIONTECH SE284.51%75 705
WUXI APPTEC CO., LTD.38.94%68 994
REGENERON PHARMACEUTICALS21.38%60 726
VERTEX PHARMACEUTICALS-14.43%52 353